Clinical Trial Update: A Study of GlcNAc on Tear Production in NGLY1-CDDG [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating N-acetylglucosamine (GlcNAc) for tear production in individuals with NGLY1 deficiency. The study is currently active but not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ngly1 Deficiency

Drugs mentioned

• GlcNAc (N-acetylglucosamine)

Snippet

Sponsor: Eva Morava-Kozicz | Conditions: NGLY1 Deficiency | Phase 2 | Status: ACTIVE_NOT_RECRUITING